Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead

S. M. Moghimi, A. J. Andersen, S. H. Hashemi, B. Lettiero, D. Ahmadvand, A. C. Hunter, T. L. Andresen, I. Hamad, J. Szebeni

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Since their introduction, poly(ethylene glycol)-phospholipid (PEG-PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG-PL engineered nanomedicines in both experimental animals and man. These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals. This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG-PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.

Original languageEnglish
Pages (from-to)175-181
Number of pages7
JournalJournal of Controlled Release
Volume146
Issue number2
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Nanomedicine
Carbon Nanotubes
Ethylene Glycol
Complement Activation
Phospholipids
Anaphylaxis
Adsorption
Blood Proteins
Hypersensitivity
Pharmaceutical Preparations

Keywords

  • Carbon nanotube
  • Complement activation
  • Liposome
  • Micelle
  • Poly(ethylene glycol)
  • Pseudoallergy

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes : The challenges ahead. / Moghimi, S. M.; Andersen, A. J.; Hashemi, S. H.; Lettiero, B.; Ahmadvand, D.; Hunter, A. C.; Andresen, T. L.; Hamad, I.; Szebeni, J.

In: Journal of Controlled Release, Vol. 146, No. 2, 09.2010, p. 175-181.

Research output: Contribution to journalArticle

Moghimi, SM, Andersen, AJ, Hashemi, SH, Lettiero, B, Ahmadvand, D, Hunter, AC, Andresen, TL, Hamad, I & Szebeni, J 2010, 'Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead', Journal of Controlled Release, vol. 146, no. 2, pp. 175-181. https://doi.org/10.1016/j.jconrel.2010.04.003
Moghimi, S. M. ; Andersen, A. J. ; Hashemi, S. H. ; Lettiero, B. ; Ahmadvand, D. ; Hunter, A. C. ; Andresen, T. L. ; Hamad, I. ; Szebeni, J. / Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes : The challenges ahead. In: Journal of Controlled Release. 2010 ; Vol. 146, No. 2. pp. 175-181.
@article{4fcdebfcda1048bda1b26b56d6d3f8e9,
title = "Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead",
abstract = "Since their introduction, poly(ethylene glycol)-phospholipid (PEG-PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG-PL engineered nanomedicines in both experimental animals and man. These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals. This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG-PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.",
keywords = "Carbon nanotube, Complement activation, Liposome, Micelle, Poly(ethylene glycol), Pseudoallergy",
author = "Moghimi, {S. M.} and Andersen, {A. J.} and Hashemi, {S. H.} and B. Lettiero and D. Ahmadvand and Hunter, {A. C.} and Andresen, {T. L.} and I. Hamad and J. Szebeni",
year = "2010",
month = "9",
doi = "10.1016/j.jconrel.2010.04.003",
language = "English",
volume = "146",
pages = "175--181",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes

T2 - The challenges ahead

AU - Moghimi, S. M.

AU - Andersen, A. J.

AU - Hashemi, S. H.

AU - Lettiero, B.

AU - Ahmadvand, D.

AU - Hunter, A. C.

AU - Andresen, T. L.

AU - Hamad, I.

AU - Szebeni, J.

PY - 2010/9

Y1 - 2010/9

N2 - Since their introduction, poly(ethylene glycol)-phospholipid (PEG-PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG-PL engineered nanomedicines in both experimental animals and man. These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals. This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG-PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.

AB - Since their introduction, poly(ethylene glycol)-phospholipid (PEG-PL) conjugates have found many applications in design and engineering of nanosized delivery systems for controlled delivery of pharmaceuticals especially to non-macrophage targets. However, there are reports of idiosyncratic reactions to certain PEG-PL engineered nanomedicines in both experimental animals and man. These reactions are classified as pseudoallergy and may be associated with cardiopulmonary disturbance and other related symptoms of anaphylaxis. Recent studies suggest that complement activation may be a contributing, but not a rate limiting factor, in eliciting hypersensitivity reactions to such nanomedicines in sensitive individuals. This is rather surprising since PEGylated structures are generally assumed to suppress protein adsorption and blood opsonization events including complement. Here, we examine the molecular basis of complement activation by PEG-PL engineered nanomedicines and carbon nanotubes and discuss the challenges ahead.

KW - Carbon nanotube

KW - Complement activation

KW - Liposome

KW - Micelle

KW - Poly(ethylene glycol)

KW - Pseudoallergy

UR - http://www.scopus.com/inward/record.url?scp=77955415384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955415384&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2010.04.003

DO - 10.1016/j.jconrel.2010.04.003

M3 - Article

C2 - 20388529

AN - SCOPUS:77955415384

VL - 146

SP - 175

EP - 181

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -